Empiric Quinidine for Asymptomatic Brugada Syndrome


The purpose of this study is to determine if Quinidine therapy (not guided by the results of electrophysiologic studies) will reduce the long-term risk of arrhythmic events in asymptomatic Brugada Syndrome.


Study Type:


Study Design:

Prevention, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study.

Official Title:

A Prospective Trial Of Empiric Quinidine Therapy For Asymptomatic Brugada Syndrome.





Drug: Quinidine
Drug: no therapy


Arms Assigned Interventions
Quinidine: Experimental
Patients with type I Brugada electrocardiogram
(either spontaneous or following a drug challenge
with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive Quinidine therapy at the discretion of the attending physician.
Drug: Quinidine
Quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.

No therapy: Active Comparator
Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
Drug: no therapy




  1.   Following the approval of the new manufacturer by the French Health Authority (the Agence Nationale de Sécurité du Médicament, the ANSM), Serecor® 300mg prolonged-release capsules are again available.
    •  Initial prescriptions of Serecor® 300mg prolonged-release capsules are restricted to cardiologists;
    • Repeat prescriptions are not restricted to cardiologists.

  2. Also, Supplies of QUINIDINE SULFATE 200 mg can be purchased directly from Rekah Pharmaceuticals in Israel by contacting Mr. Yaacov Elgrabli at yaacov.c@rekah.co.il Quinidine should only be taken under medical supervision.



The trial is registered at:

Log In

Sign Up
Forgot my password